I am concerned about the potential of a second Chinese base in Africa, especially on the Atlantic coast.

I think we should also let members know that the Chinese are coming in with some creative financing.

we appreciate you. We appreciate your bravery, your strength, your love for the ones that you lost.

I think he should resign. I swear to God, he should resign, and he should be disbarred.

I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is as follows: After section 20114, add the following: SEC. 20115. GAO REPORT ON WIND ENERGY IMPACTS. The Comptroller…

Again, I thank the chairman for his help and his support. I thank the Congressman, Dr. Andy Harris, for traveling the great distance to New Jersey to be at the hearing that we had in the field. I thank Congressman Chris Smith for his…

Like canaries in coal mines, the recent spate of tragic whale and dolphin deaths and a well-founded suspicion that geophysical surveys, including the use of sonar may be a contributing cause, has brought new light and increased scrutiny to…

patients would be better off if PBMs and other supply chain entities were paid flat fees

PBMs make more money when a drug's list price increases, while patients bear the financial burden.

This level of concentration gives these PBMs market power over data, drug coverage, and contracting--80 percent.

The hyper-consolidation, with little to no regulatory oversight, creates inappropriate negotiating leverage that discourages competition and makes it difficult to achieve transparency, affordability, and timely access for patients.

it would be better for patients if the supply chain was delinked from list prices

it would be better for patients if the supply chain was delinked from list prices

patients would be better off if PBMs and other supply chain entities were paid flat fees

pharmacy benefit managers are key players, or should be, in alleviating patients' financial burden at the pharmacy counter

PBMs make more money when a drug's list price increases, while patients bear the financial burden.

High list prices hurt patients who must pay these prices. If list prices were lower, out-of-pocket payments based on list prices would be lower and more affordable.

High list prices hurt patients who must pay these prices. If list prices were lower, out-of-pocket payments based on list prices would be lower and more affordable.